Ziopharm Shares Are Trading Lower After Slashing Workforce By Over 50%
Benzinga
28 Sep 2021
Ziopharm Oncology Inc (NASDAQ:ZIOP) announced a restructuring enabling the Company to advance its TCR program.
The Company will eliminate approximately 60 positions and expects the changes will extend the cash runway into 1H of 2023. Earlier, ZIOP expected cash runway into Q4 of 2022.
As of June 30, 2021, the Company had approximately $76.7 million of cash and cash equivalents.
The Company also announced that dosing in its TCR-T Library Phase 1/2 trial will start in 1H of 2022 after experiencing unforeseen delays caused by inadequate resources at its contract manufacturer.
The Company is investing in its manufacturing capabilities to accelerate patient dosing. It is committed to operationalizing internal manufacturing capabilities in 1H of 2022 to support the first patient dosing.
Price Action: ZIOP stock is down 15.1% at $1.8 during the premarket session on the last check Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.